Abstract
The immune response of 42 gastrointestinal and ovarian cancer patients at 1 month after exposure to murine monoclonal antibodies (B72.3 and CC49) reactive with the tumor associated antigen TAG-72 was studied. The incidence of human anti-mouse antibody response was 89% to B72.3 and 70% to CC49. To evaluate the antiidiotypic immune response, we developed a serological assay based on affinity chromatography to remove the interference due to the presence of TAG-72, antiisotypic, and antiallotypic immunoglobulins in the serum. Seventy-eight percent of patients who received B72.3 developed an antiidiotypic response; in 33% of the patients, this was the only immune response detected. The antiidiotypic immune response after treatment with CC49 was present in 54% of the patients. Twelve percent of the patients who received CC49 developed an antiidiotypic response in the absence of antiisotypic or antiallotypic immune response. The lower immunogenicity of the variable region of CC49 is encouraging when considering the use of chimeric or humanized antibodies derived from the murine monoclona1 antibody CC49 in clinical studies.
| Original language | English |
|---|---|
| Pages (from-to) | 96-106 |
| Number of pages | 11 |
| Journal | Journal of Clinical Immunology |
| Volume | 17 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1997 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology
Cite this
Antiidioptypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. / Blanco, Ignacio; Kawatsu, Ryuichi; Harrison, Katherine; Leichner, Peter; Augustine, Samuel C.; Baranowska-Kortylewicz, Janina; Tempero, Margaret; Colcher, David.
In: Journal of Clinical Immunology, Vol. 17, No. 1, 1997, p. 96-106.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antiidioptypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72
AU - Blanco, Ignacio
AU - Kawatsu, Ryuichi
AU - Harrison, Katherine
AU - Leichner, Peter
AU - Augustine, Samuel C.
AU - Baranowska-Kortylewicz, Janina
AU - Tempero, Margaret
AU - Colcher, David
PY - 1997
Y1 - 1997
N2 - The immune response of 42 gastrointestinal and ovarian cancer patients at 1 month after exposure to murine monoclonal antibodies (B72.3 and CC49) reactive with the tumor associated antigen TAG-72 was studied. The incidence of human anti-mouse antibody response was 89% to B72.3 and 70% to CC49. To evaluate the antiidiotypic immune response, we developed a serological assay based on affinity chromatography to remove the interference due to the presence of TAG-72, antiisotypic, and antiallotypic immunoglobulins in the serum. Seventy-eight percent of patients who received B72.3 developed an antiidiotypic response; in 33% of the patients, this was the only immune response detected. The antiidiotypic immune response after treatment with CC49 was present in 54% of the patients. Twelve percent of the patients who received CC49 developed an antiidiotypic response in the absence of antiisotypic or antiallotypic immune response. The lower immunogenicity of the variable region of CC49 is encouraging when considering the use of chimeric or humanized antibodies derived from the murine monoclona1 antibody CC49 in clinical studies.
AB - The immune response of 42 gastrointestinal and ovarian cancer patients at 1 month after exposure to murine monoclonal antibodies (B72.3 and CC49) reactive with the tumor associated antigen TAG-72 was studied. The incidence of human anti-mouse antibody response was 89% to B72.3 and 70% to CC49. To evaluate the antiidiotypic immune response, we developed a serological assay based on affinity chromatography to remove the interference due to the presence of TAG-72, antiisotypic, and antiallotypic immunoglobulins in the serum. Seventy-eight percent of patients who received B72.3 developed an antiidiotypic response; in 33% of the patients, this was the only immune response detected. The antiidiotypic immune response after treatment with CC49 was present in 54% of the patients. Twelve percent of the patients who received CC49 developed an antiidiotypic response in the absence of antiisotypic or antiallotypic immune response. The lower immunogenicity of the variable region of CC49 is encouraging when considering the use of chimeric or humanized antibodies derived from the murine monoclona1 antibody CC49 in clinical studies.
UR - http://www.scopus.com/inward/record.url?scp=0030614926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030614926&partnerID=8YFLogxK
U2 - 10.1023/A:1027396714623
DO - 10.1023/A:1027396714623
M3 - Article
VL - 17
SP - 96
EP - 106
JO - Journal of Clinical Immunology
JF - Journal of Clinical Immunology
SN - 0271-9142
IS - 1
ER -